Medical cannabis access programs are associated with year-over-year declines in fatal workplace accidents, according to data published online ahead of print in The International Journal of Drug Policy. Authors concluded, “This reduction may be the result of workers substituting marijuana in place of alcohol and other substances that can impair cognitive function and motor skills.”
The use of herbal cannabis is associated with reductions in self-perceived insomnia severity, according to data published in the online, open-access journal Medicines. Authors concluded, “The widespread apparent use of cannabis as a sleep aid underscores the importance of further medical research regarding its risk-benefit profile and the effectiveness of cannabis as a substitute for other substances.”
Reps. Tulsi Gabbard (HI-02) and Carlos Curbelo (FL-26) led a group of bipartisan lawmakers in introducing The Marijuana Data Collection Act. The act calls upon the National Academy of Sciences (NAS) to collect and synthesize relevant data and to generate a formal report to Congress quantifying the impact of statewide marijuana legalization on matters specific to public health, safety, the economy, and criminal justice, among other issues.
Older Americans are using cannabis more frequently than ever before, according to a review of demographic data published in the journal Gerontology and Geriatric Medicine.
Republican Gov. Mary Fallin yesterday signed into law emergency regulations amending SQ 788 — the state’s voter-initiated medical marijuana access law. The Oklahoma State Medical Association, which opposed the passage of SQ 788, lobbied for many of the amendments. Governor Fallin also was a vocal critic of the initiative campaign.
The enactment of medical cannabis access laws is associated with significant reductions in prescription opioid use among Medicaid enrollees, according to just-published data in the journal Addiction. Authors reported, “For Schedule III opioid prescriptions, medical cannabis legalization was associated with a 29.6 percent reduction in number of prescriptions, 29.9 percent reduction in dosage, and 28.8 percent reduction in related Medicaid spending.”
Regulators at the US Food and Drug Administration today granted market approval for Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.
More than two-thirds of chronic pain patients registered to legally access medical cannabis products substitute marijuana for prescription opioids, according to data published in The Journal of Headache and Pain Among those patients diagnosed specifically with headache/migraine, cannabis was frequently reported as a substitute for other medications – including opiates (43 percent), anti-depressants (39 percent), NSAIDS (21 percent), triptans (8 percent), and anti-convulsants (8 percent).
Patients enrolled in New York state’s medical cannabis program reduce their use of opioids and spend less money on prescription medications, according to data published online in the journal Mental Health Clinician. “After three months treatment, medical cannabis improved [subjects’] quality of life, reduced pain and opioid use, and lead to cost savings,” authors concluded.
The frequent use of cannabis is not associated with changes in brain structure, according to data published online ahead of print in the journal Addiction. Authors reported, “[N]ormal variation in cannabis use is statistically unrelated to individual differences in brain morphology as measured by subcortical volume.”